3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
101
Radiotherapy
50
Magnetic Resonance Spectroscopy
38
Radiation
28
Specimen Handling
25
pembrolizumab
23
Bevacizumab
23
Lomustine
16
Nivolumab
14
Surgical Procedures, Operative
11
atezolizumab
8
Cyclophosphamide
8
Biopsy
8
abemaciclib
7
Ipilimumab
7
Carboplatin
7
fludarabine
6
Radiotherapy, Intensity-Modulated
6
Aminolevulinic Acid
6
olaparib
5
Metformin
5
Drug Therapy
5
Diet, Ketogenic
5
Dianhydrogalactitol
5
regorafenib
4
poly ICLC
4
cemiplimab
4
Radiosurgery
4
Photons
4
Leukapheresis
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Interleukin-15
×
1 year
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled